Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

4(50.0%)

N/A

2(25.0%)

Phase 3

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 2(4)

N/A(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07372807Phase 1Not Yet Recruiting

Ripertamab for the Treatment of Myasthenia Gravis

Role: lead

NCT07355257Phase 2Not Yet Recruiting

TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Role: lead

NCT06210633Recruiting

Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke

Role: lead

NCT06388148Not ApplicableRecruiting

Endovascular Treatment for eXtra-Large Ischemic Stroke

Role: lead

NCT06885762Phase 2Not Yet Recruiting

Efgartigimod for the Treatment of Guillain-Barré Syndrome

Role: lead

NCT06858722Phase 3Not Yet Recruiting

Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

Role: lead

NCT06684184Phase 2Not Yet Recruiting

Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)

Role: lead

NCT06373042Phase 2Not Yet Recruiting

Tirofiban for Successful Endovascular Stroke Thrombectomy

Role: lead

NCT05891509Not ApplicableRecruiting

DTI-guided Minimally Invasive Hematoma Evacuation for Intracerebral Hemorrhage

Role: lead

All 9 trials loaded